Antitumor activity of ADCT-402 in a range of tumor models. (A) In vivo antitumor activity of ADCT-402 in SC implanted CD19-expressing Burkitt lymphoma-derived Daudi xenograft model. ADCT-402 was administered IV at a group mean tumor volume of 130 mm³ as a single dose at 0.1 or 0.3 mg/kg. (B) In vivo antitumor activity of ADCT-402 in SC implanted CD19-expressing diffuse large B-cell lymphoma-derived WSU-DLCL2 xenograft model. ADCT-402 was administered IV at a group mean tumor volume of 120 mm³ as a single dose at 0.3 or 1 mg/kg. (A-B) Mean ± SEM from animal group sizes of 10 mice. (C) In vivo antitumor activity of ADCT-402 in a disseminated CD19-expressing ALL-derived NALM-6 model. Kaplan-Meier survival plots show percentage of animal survival over 90 days in an experiment in which ADCT-402 was administered at a single dose of 0.33 or 1 mg/kg in comparison with vehicle or nontargeting ADC administered as a single dose of 1 mg/kg (each group, n = 10).